Skip to main content
An intranal body illustration of the FARAWAVE catheter

Cardiac Ablation & Mapping 

Advancing the diagnosis and treatment of patients with atrial fibrillation and other heart rhythm disorders.

Innovation in atrial fibrillation treatment

A growing number of people across the U.S. are developing atrial fibrillation (AFib), the most common arrhythmia1. Catheter ablation for AFib has shown superior effectiveness over antiarrhythmic drugs in reducing AFib recurrences2,  however only a small percentage of AFib patients receive this treatment today.

Early diagnosis followed by safe and effective ablation treatments can slow disease progression, reduce AFib recurrences, and improve patients’ quality of life.3

The burden of atrial fibrillation

12.1 M

U.S. patients with AFib by 20304

1 in 7

Strokes caused by AFib5

>450k

Hospitalizations with AFib annually in US6

Full suite of cardiac ablation therapies.

Boston Scientific is committed to advancing the treatment of Atrial Fibrillation.

FARAPULSE™ Pulsed Field Ablation System

The most clinically proven PFA system is now FDA approved – setting a new standard for treating paroxysmal atrial fibrillation. The FARAPULSE PFA System is purpose-built to optimize the AFib procedure and serve the growing AFib population.

  • Unparalleled experience with more than 70,000 patients treated globally
  • Efficient, predictable procedures may increase patient throughput
  • Over a decade of design and optimization

What is PFA?

Pulsed Field Ablation (PFA) is a non-thermal mechanism of action that has the potential to transform cardiac ablation. Offering several benefits over traditional thermal energy sources, PFA can be optimized to target myocardial tissue while sparing surrounding anatomy.

Why choose FARAPULSE PFA?

FARAPULSE’s proven safety, efficacy, and efficiency are functions of the optimized catheter design, waveform, and dosing strategy.

Unparalleled clinical evidence

  • The ADVENT Pivotal Trial, the only randomized controlled trial comparing PFA to cryoablation and radiofrequency ablation, met primary safety and efficacy endpoints while delivering statistically significant improvement in efficiency.7
  • MANIFEST-17K is the largest, real-world safety registry of any PFA system.8 In the more than 17k patients studied, zero cases of:
    • Esophageal fistula
    • Pulmonary vein stenosis
    • Phrenic nerve paralysis

Operational efficiencies

  • Standardized, simple workflow
  • Flexible imaging guidance and compatible with any mapping system
  • Reproducible procedure

Economic value for administrators

  • 42% average reduction in ablation time7 may increase capacity to add more cases
  • Predictable cases improve schedule consistency

Discover how Pulsed Field Ablation with FARAPULSE can positively impact clinical practice and improve efficiencies across your cardiovascular service line (CVSL).

Explore FARAPULSE

FARAPULSE value brief

Read how FARAPULSE can improve the clinical outcomes and reduce the costs of treating your patients with cardiac arrhythmias.

Filename
BSC_FARAPULSE_Value_Brief_CORP-1959505_AA_AUG2024.pdf
Size
682 KB
Format
application/pdf
Download the FARAPULSE value brief
Image of POLARx ballon device showing the two balloon sizes (28mm and 31mm) in one catheter

POLARx™ Cryoablation System

The POLARx Cryoablation System redefines what's possible in cardiac cryoablation. Featuring POLARx™ FIT, the only dual-diameter cryoballoon in one catheter, the POLARx System provides:

  • Greater occlusion capability
  • Greater ablation confidence
  • Greater workflow capabilities
Learn more about POLARx

Cardiac ablation reimbursement

Coding and Payment Guides

View cardiac ablation reimbursement

Contact us

Get in touch with a sales representative to discuss how our portfolio of product and solutions can deliver measurable outcomes in the cardiovascular service line.

Contact form

References:

1. Centers for Disease Control and Prevention. Atrial Fibrillation.  https://www.cdc.gov/heartdisease/atrial_fibrillation.htm. Accessed September 7, 2023.

2. Ang R, Earley MJ. The role of catheter ablation in the management of atrial fibrillation. Clin Med (Lond). 2016;16(3):267-271. 

3. Schwennesen HT, Andrade JG, Wood KA, Piccini JP. Ablation to Reduce Atrial Fibrillation Burden and Improve Outcomes: JACC Review Topic of the Week. J Am Coll Cardiol 2023;82:1039-1050.

4. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013 Oct 15;112(8):1142-7. doi: 10.1016/j.amjcard.2013.05.063. Epub 2013 Jul 4. PMID: 23831166.

5. Heart Rhythm Society. (2019). Complications from Atrial Fibrillation. Accessed May 9, 2019.

6. Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–528.

7. Reddy, Vivek Y., et al. "Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation." New England Journal of Medicine 389.18 (2023): 1660-1671.

8. Reddy & Ekanem, et al. Multi-National Survey on the Safety of the Post-Approval Clinical Use of Pulsed Field Ablation in 17,000+Patients (MANIFEST-17K). AHA 2023.